Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
G Agliardi, AR Liuzzi, A Hotblack, D De Feo… - Nature …, 2021 - nature.com
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …
Dual-wavelength photosensitive nano-in-micro scaffold regulates innate and adaptive immune responses for osteogenesis
The immune response of a biomaterial determines its osteoinductive effect. Although the
mechanisms by which some immune cells promote regeneration have been revealed, the …
mechanisms by which some immune cells promote regeneration have been revealed, the …
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the
treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or …
treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or …
Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based …
J Rossowska, N Anger, A Szczygieł… - Journal of Experimental …, 2018 - Springer
Background The excessive amounts of immunosuppressive factors present in a tumor
microenvironment (TME) reduce the effectiveness of cancer vaccines. The main objective of …
microenvironment (TME) reduce the effectiveness of cancer vaccines. The main objective of …
Tumor-resident dendritic cells and macrophages modulate the accumulation of TCR-engineered T cells in melanoma
Ongoing clinical trials explore T cell receptor (TCR) gene therapy as a treatment option for
cancer, but responses in solid tumors are hampered by the immunosuppressive …
cancer, but responses in solid tumors are hampered by the immunosuppressive …
Intratumoral lentivector-mediated TGF-β1 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and …
J Rossowska, N Anger, A Szczygieł… - Frontiers in …, 2017 - frontiersin.org
Vaccination with dendritic cells (DCs) stimulated with tumor antigens can induce specific
cellular immune response that recognizes a high spectrum of tumor antigens. However, the …
cellular immune response that recognizes a high spectrum of tumor antigens. However, the …
ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities
JA Leleux, TC Albershardt, AJ Parsons, J Ter Meulen… - Vaccine, 2020 - Elsevier
Therapeutic cancer vaccines must induce high levels of tumor-specific cytotoxic CD8 T cells
to be effective. We show here that tumor-antigen specific effector and memory T cell …
to be effective. We show here that tumor-antigen specific effector and memory T cell …
Intradermal immunization with rAAV1 vector induces robust memory CD8+ T cell responses independently of transgene expression in DCs
A Ghenassia, DA Gross, S Lorain, F Tros, D Urbain… - Molecular Therapy, 2017 - cell.com
Recombinant adeno-associated viral (rAAV) vectors exhibit interesting properties as vaccine
carriers for their ability to induce long-lasting antibody responses. However, rAAV-based …
carriers for their ability to induce long-lasting antibody responses. However, rAAV-based …
[引用][C] Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
D Escors Murugarren, AI Bocanegra Gondán… - International Journal of …, 2022 - MDPI